{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:51:23Z","timestamp":1785898283204,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1280-6","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T01:24:34Z","timestamp":1491614674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience"],"prefix":"10.1186","volume":"19","author":[{"given":"Gianfranco","family":"Lauletta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Russi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Dammacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,8]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553\u201362.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1280_CR2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/infdis\/jiw332","volume":"214","author":"M Zeremski","year":"2016","unstructured":"Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis progression in patients with chronic hepatitis C virus infection. J Infect Dis. 2016;214:1164\u201370.","journal-title":"J Infect Dis."},{"key":"1280_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.cmi.2016.07.019","volume":"22","author":"T Vescovo","year":"2016","unstructured":"Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853\u201361.","journal-title":"Clin Microbiol Infect."},{"key":"1280_CR4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmi.2016.07.035","volume":"22","author":"S Lanini","year":"2016","unstructured":"Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22:833\u20138.","journal-title":"Clin Microbiol Infect."},{"key":"1280_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2049936115585942","volume":"3","author":"P Cacoub","year":"2016","unstructured":"Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3\u201314.","journal-title":"Ther Adv Infect Dis."},{"key":"1280_CR6","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","volume":"327","author":"V Agnello","year":"1992","unstructured":"Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490\u20135.","journal-title":"N Engl J Med."},{"key":"1280_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2249.1992.tb03001.x","volume":"87","author":"F Dammacco","year":"1992","unstructured":"Dammacco F, Sansonno D. Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. Clin Exp Immunol. 1992;87:352\u20136.","journal-title":"Clin Exp Immunol."},{"key":"1280_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2000-9613","volume":"20","author":"F Dammacco","year":"2000","unstructured":"Dammacco F, Sansonno D, Piccoli C, Racanelli V, D\u2019Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Semin Liver Dis. 2000;20:143\u201357.","journal-title":"Semin Liver Dis."},{"key":"1280_CR9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-016-0410-9","volume":"16","author":"F Dammacco","year":"2016","unstructured":"Dammacco F, Racanelli V, Russi S, Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exp Med. 2016;16:233\u201342.","journal-title":"Clin Exp Med."},{"key":"1280_CR10","doi-asserted-by":"crossref","first-page":"502156","DOI":"10.1155\/2012\/502156","volume":"2012","author":"G Lauletta","year":"2012","unstructured":"Lauletta G, Russi S, Conteduca V, Sansonno L. Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol. 2012;2012:502156.","journal-title":"Clin Dev Immunol."},{"key":"1280_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MD.0b013e31829d2abc","volume":"92","author":"G Lauletta","year":"2013","unstructured":"Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection. Medicine (Baltimore). 2013;92:245\u201356.","journal-title":"Medicine (Baltimore)"},{"key":"1280_CR12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0002-9343(87)90904-1","volume":"83","author":"L Bonomo","year":"1987","unstructured":"Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med. 1987;83:726\u201330.","journal-title":"Am J Med."},{"key":"1280_CR13","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood.V78.12.3142.3142","volume":"78","author":"M Casato","year":"1991","unstructured":"Casato M, Lagan\u00e0 B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-\u03b1 for type II essential mixed cryoglobulinemia. Blood. 1991;78:3142\u20137.","journal-title":"Blood."},{"key":"1280_CR14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1208642","volume":"369","author":"F Dammacco","year":"2013","unstructured":"Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369:1035\u201345.","journal-title":"N Engl J Med."},{"key":"1280_CR15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.20958","volume":"52","author":"P Cacoub","year":"2005","unstructured":"Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005;52:911\u20135.","journal-title":"Arthritis Rheum."},{"key":"1280_CR16","first-page":"933","volume":"29","author":"C Mazzaro","year":"2011","unstructured":"Mazzaro C, Monti G, Saccardo F, Zignego AL, Ferri C, De Vita S, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol. 2011;29:933\u201341.","journal-title":"Clin Exp Rheumatol."},{"key":"1280_CR17","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","volume":"101","author":"D Sansonno","year":"2003","unstructured":"Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon \u03b1 with an anti-CD20. Blood. 2003;101:3818\u201326.","journal-title":"Blood."},{"key":"1280_CR18","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101:3827\u201334.","journal-title":"Blood."},{"key":"1280_CR19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","volume":"116","author":"F Dammacco","year":"2010","unstructured":"Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al. Pegylated interferon-\u03b1, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116:343\u201353.","journal-title":"Blood."},{"key":"1280_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","volume":"62","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al. PegIFN\u03b1\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62:24\u201330.","journal-title":"J Hepatol."},{"key":"1280_CR21","first-page":"47","volume":"9","author":"J Zhang","year":"2016","unstructured":"Zhang J, Nguyen D, Hu KQ. Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci (Boston). 2016;9:47\u201354.","journal-title":"N Am J Med Sci (Boston)"},{"key":"1280_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","journal-title":"J Hepatol"},{"key":"1280_CR23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932\u201354.","journal-title":"Hepatology"},{"key":"1280_CR24","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","volume":"75","author":"D Saadoun","year":"2016","unstructured":"Saadoun D, Thibault V, Si Ahmed SN, Alric L, Mallet M, Guillaud C, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777\u201382.","journal-title":"Ann Rheum Dis."},{"key":"1280_CR25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","volume":"63","author":"ME Sise","year":"2016","unstructured":"Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408\u201317.","journal-title":"Hepatology."},{"key":"1280_CR26","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","volume":"64","author":"L Gragnani","year":"2016","unstructured":"Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473\u201382.","journal-title":"Hepatology."},{"key":"1280_CR27","doi-asserted-by":"publisher","unstructured":"Bonacci M, Lens S, Londo\u00f1o MC, Mari\u00f1o Z, Cid MC, Ramos-Casals M, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. doi: 10.1016\/j.cgh.2016.09.158 .","DOI":"10.1016\/j.cgh.2016.09.158"},{"key":"1280_CR28","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/rheumatology\/keu271","volume":"53","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Isola M, Corazza L, Ramos-Casals M, Retamozo S, Ragab GM, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford). 2014;53:2209\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"1280_CR29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","volume":"57","author":"JC Brouet","year":"1974","unstructured":"Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57:775\u201388.","journal-title":"Am J Med."},{"key":"1280_CR30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/clinchem\/38.6.798","volume":"38","author":"L Musset","year":"1992","unstructured":"Musset L, Diemert MC, Taibi F, Du Thi Huong L, Cacoub P, Leger JM, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem. 1992;38:798\u2013802.","journal-title":"Clin Chem"},{"key":"1280_CR31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005792-200107000-00004","volume":"80","author":"O Trejo","year":"2001","unstructured":"Trejo O, Ramos-Casals M, Garc\u00eda-Carrasco M, Yag\u00fce J, Jim\u00e9nez S, de la Red G, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252\u201362.","journal-title":"Medicine (Baltimore)"},{"key":"1280_CR32","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","volume":"55","author":"S Sollima","year":"2016","unstructured":"Sollima S, Milazzo L, Peri AM, Torre A, Antinori S, Galli M. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55:2084\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"1280_CR33","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hep.25499","volume":"55","author":"SK Hartridge-Lambert","year":"2012","unstructured":"Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55:634\u201341.","journal-title":"Hepatology."},{"key":"1280_CR34","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","volume":"25","author":"L Arcaini","year":"2014","unstructured":"Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJM, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25:1404\u201310.","journal-title":"Ann Oncol."},{"key":"1280_CR35","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","volume":"128","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128:2527\u201332.","journal-title":"Blood."},{"key":"1280_CR36","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2016-05-718643","volume":"128","author":"HA Torres","year":"2016","unstructured":"Torres HA, McDonald GB. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood. 2016;128:1449\u201357.","journal-title":"Blood."},{"key":"1280_CR37","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","volume":"54","author":"D Saadoun","year":"2006","unstructured":"Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum. 2006;54:3696\u2013706.","journal-title":"Arthritis Rheum."},{"key":"1280_CR38","doi-asserted-by":"crossref","first-page":"e0144629","DOI":"10.1371\/journal.pone.0144629","volume":"10","author":"E Reyes-Avil\u00e9s","year":"2015","unstructured":"Reyes-Avil\u00e9s E, Kostadinova L, Rusterholtz A, Cruz-Lebr\u00f3n A, Falck-Ytter Y, Anthony DD. Presence of rheumatoid factor during chronic HCV infection is associated with expansion of mature activated memory B-cells that are hypo-responsive to B-cell receptor stimulation and persist during the early stage of IFN free therapy. PLoS One. 2015;10:e0144629.","journal-title":"PLoS One."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1280-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T05:12:01Z","timestamp":1601874721000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1280-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1280-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,8]]},"article-number":"74"}}